Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Policy Analysis
August 2005

FDA Again Stalls on Over-the-Counter Status for Emergency Contraception

Reproductive rights are under attack. Will you help us fight back with facts?

Donate

More than a year and a half after two of its expert advisory committees voted 23 to 4 to recommend approval for unrestricted access, the U.S. Food and Drug Administration (FDA) has indefinitely postponed any decision to allow nonprescription status for Plan B emergency contraception (EC)—popularly known as the "morning-after pill."

The FDA is delaying any action to make the method available while they gather public comments. At the December 16, 2003, advisory committee hearing, medical and health organizations provided expert testimony in favor of the switch to over-the-counter status. In addition to the FDA’s advisory committees and staff scientists, major medical groups including the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the American Public Health Association have endorsed over-the-counter status. Women in Western Europe and Canada can already buy similar products without a prescription.

The FDA is holding up timely access to EC while they debate the legality and feasibility of making the method available to adult women over-the-counter and to women aged 16 and younger as a prescription-only drug. The FDA actually recommended that Plan B’s manufacturers request this dual status as a way to address FDA concerns that young women will misuse or abuse the pills. Studies included in the original April, 2003, application indicate the drug is safe for young teens and show that easier access does not lead to greater risk-taking by teens. Medical experts argue that teens are the very people who may need emergency contraception most, because they are more likely than adults to have unprotected sex and have less experience with regular contraception.

Emergency contraception consists of the same hormone (a progestin) found in ordinary birth control pills. It is not the same as the abortion pill, mifepristone (an anti-progestin). Timely access to emergency contraception is critical, because the pills are more effective the sooner they are taken. Delays caused by the need to obtain and fill prescriptions (particularly over weekends and holidays) can reduce the product’s effectiveness and may prevent many women from starting treatment in time to avoid a pregnancy. Research from the Guttmacher Institute suggests that in 2000, use of emergency contraceptives averted more than 100,000 unintended pregnancies, helping women to avoid an estimated 51,000 abortions.

Legislatures in a number of states have already taken steps to improve access to emergency contraceptives. Seven states allow pharmacists in collaborative practice agreements with physicians to dispense the pills, and six states require hospital emergency rooms to provide treatment to women who have been sexually assaulted. Major medical groups are also recommending that doctors dispense the drug in advance for women to keep in their medicine cabinet.

Click on the links below for more information.

Steps being taken to improve access to emergency contraception

To learn about what states are doing to improve access to emergency contraception, see Increasing Access to Emergency Contraception Through Community Pharmacies: Lessons from Washington State and State Policies in Brief: Access to Emergency Contraception.

First published online: August 29, 2005

Share

Printer-friendly version

US Policy Resources

More
Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2025 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.